The Latest Analyst Ratings for Catalyst Pharmaceuticals
Portfolio Pulse from Benzinga Insights
In the last quarter, Catalyst Pharmaceuticals (NASDAQ:CPRX) received 4 bullish analyst ratings with an average 12-month price target of $24.25, increasing by 10.23% over the past month.
June 21, 2023 | 6:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Catalyst Pharmaceuticals received 4 bullish analyst ratings with an average 12-month price target of $24.25, increasing by 10.23% over the past month.
The 4 bullish analyst ratings and the increase in the average 12-month price target by 10.23% over the past month indicate a positive outlook for Catalyst Pharmaceuticals' stock price in the short term. This is likely to result in an upward movement of the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100